Minerva Neurosciences, Inc. (NERV) Stock: Price, Forecast & Analyst Target
Minerva Neurosciences, Inc. (NERV) — price $3.36 (+2.44%), as of the Oct 5, 2026 trading session; market cap $157M.
Educational signal · not a buy or sell recommendation · How to read this
Minerva Neurosciences, Inc. · NERV · NASDAQ
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.36 | |
| Change on the day | +2.44% | |
| 52-week range | $2.08 – $12.46 | |
| Market capitalisation | $157M | |
| Shares traded on the day | 1.5K |
Price & events
Other perspectives
Council score for Minerva Neurosciences (NERV): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the NERV film — every key number, told as a short cinematic story
~2 min · open the film
What is Minerva Neurosciences (NERV), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Minerva Neurosciences, Inc. (NERV) is listed on NASDAQ. It employs 7 people and is led by Remy Luthringer. In Q2 FY2026 it reported revenue of $0 and net income of $17M. The market values it at $157M.
What do the latest results show for Minerva Neurosciences (NERV)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0. Against analyst estimates the company has EPS beat 5 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | $17M | $0.22 (diluted) |
| Q1 FY2026 | $0 | -$125M | -$2.86 (diluted) |
| Q4 FY2025 | $0 | -$284M | -$25.51 (diluted) |
| Q3 FY2025 | $0 | -$3M | -$0.36 (diluted) |
What are the financial strengths and risks for Minerva Neurosciences (NERV)?
Short answer
The distress and quality screens read Altman Z -24.15 · Piotroski F 1. Trailing ratios: ROE 359.8% · current ratio 17.65 · earnings yield -174.6%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -24.15 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Minerva Neurosciences (NERV)?
Short answer · as of
Current published price targets run low $10.00 · high $10.00 · consensus $10.00 · median $10.00 against a quoted price of $3.36 (as of Oct 5, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $10.00 – $10.00
- Consensus target
- $10.00
- Median target
- $10.00
Consensus record · Captured .
Measured against a quoted price of $3.36 (as of Oct 5, 2026).
What has been published about Minerva Neurosciences (NERV)?
What Investors Ask About Minerva Neurosciences (NERV)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is NERV a good stock to buy?
Stock Expert AI does not rate NERV buy, sell or hold. Minerva Neurosciences, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NERV stock price today?
The last price recorded on this page for Minerva Neurosciences, Inc. (NERV) is $3.36, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NERV price target?
The analyst consensus price target for Minerva Neurosciences, Inc. (NERV) is $10.00 (range $10.00 to $10.00, median $10.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for NERV?
Evaluate NERV on fundamentals, analyst consensus, and risk factors. Analysts target $10.00 (+198%). Lead product candidate roluperidone targets the treatment of schizophrenia, addressing a significant unmet need in CNS disorders. Not financial advice.
How frequently does NERV data refresh on this page?
NERV's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NERV's recent stock price performance?
Minerva Neurosciences, Inc. (NERV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on unmet needs in CNS disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NERV overvalued or undervalued right now?
Minerva Neurosciences, Inc. (NERV) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $10.00 (+198%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of NERV?
Fractional-share availability for Minerva Neurosciences, Inc. (NERV) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (18 figures)
The 18 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 12 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $3.36 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T13:45:05.490Z. | |
px.change | Change on the day | +2.44% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $157M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T13:44:10.000Z. Captured from FMP at 2026-10-05T13:45:02.885Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.08 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.5K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $17M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $10.00 · high $10.00 · consensus $10.00 · median $10.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $10.00 – $10.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $10.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $10.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $2.08 – $12.46 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.employees | Employees | 7 | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
id.ceo | Chief executive | Remy Luthringer | UNRECORDED | Stored company-profile observation — Captured 2026-10-01 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-17 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -24.15 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 359.8% · current ratio 17.65 · earnings yield -174.6% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.